# TRUST-II (NCT04919811)

> Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04919811
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Nuvation Bio Inc.
- Conditions: Non Small Cell Lung Cancer
- Interventions: Taletrectinib
- Enrollment: 217
- Primary outcome: Objective response rate (ORR) by independent radiology review committee (IRC)

## Commentary we found

- X threads: 10
- YouTube: 7
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=trust-ii-nct04919811

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04919811", "email": "<work email>"}; the inbox owner confirms by the emailed link.